Abeona Therapeutics (NASDAQ:ABEO) Director Sells $65,120.00 in Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO) Director Leila Alland sold 11,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $5.92, for a total transaction of $65,120.00. Following the completion of the transaction, the director owned 162,614 shares of the company’s stock, valued at $962,674.88. The trade was a 6.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Abeona Therapeutics Stock Performance

NASDAQ ABEO opened at $6.40 on Friday. The firm’s 50 day simple moving average is $5.64 and its 200 day simple moving average is $5.26. The firm has a market capitalization of $364.74 million, a price-to-earnings ratio of 6.60 and a beta of 1.34. The company has a current ratio of 5.89, a quick ratio of 5.70 and a debt-to-equity ratio of 0.03. Abeona Therapeutics Inc. has a 1 year low of $4.00 and a 1 year high of $7.54.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.03. The firm had revenue of $8.72 million for the quarter, compared to analyst estimates of $4.57 million. As a group, research analysts expect that Abeona Therapeutics Inc. will post -0.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Abeona Therapeutics in a research note on Thursday, May 28th. Stifel Nicolaus set a $17.00 target price on shares of Abeona Therapeutics in a report on Tuesday, March 17th. Weiss Ratings upgraded shares of Abeona Therapeutics from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, June 29th. Wall Street Zen raised shares of Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, June 1st. Finally, Oppenheimer reiterated an “outperform” rating on shares of Abeona Therapeutics in a research report on Monday, March 9th. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.00.

Institutional Investors Weigh In On Abeona Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ABEO. Royal Bank of Canada increased its holdings in Abeona Therapeutics by 49.6% in the 1st quarter. Royal Bank of Canada now owns 6,500 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 2,155 shares in the last quarter. Rangeley Capital LLC grew its holdings in shares of Abeona Therapeutics by 4.2% during the first quarter. Rangeley Capital LLC now owns 60,000 shares of the biopharmaceutical company’s stock worth $269,000 after purchasing an additional 2,400 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Abeona Therapeutics by 38.6% during the first quarter. Renaissance Technologies LLC now owns 161,082 shares of the biopharmaceutical company’s stock worth $722,000 after purchasing an additional 44,882 shares during the last quarter. Sei Investments Co. increased its stake in shares of Abeona Therapeutics by 142.4% in the first quarter. Sei Investments Co. now owns 172,460 shares of the biopharmaceutical company’s stock valued at $773,000 after buying an additional 101,307 shares during the period. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Abeona Therapeutics in the first quarter valued at approximately $154,000. Institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.